Monday, 26 October 2026European Markets

ADYEN Stock Is 26% Down So Far Today

Loading stream...

ADYEN, a leading payment platform provider based in the Netherlands, has recently seen a significant setback in its stock market performance. With shares plummeting 26.81% to EUR1,077.60 across four trading sessions, the establishment is clearly experiencing an overall negative trajectory. The last recorded closing price was a dismal EUR1472.40, which stands in stark contrast to their 52-week peak of EUR1878.60.

ADYEN's Financials

Despite the downturn, ADYEN still manages to boast a trailing earnings per share (EPS) of EUR18.31 and an earnings-to-price (PE) ratio of 58.85. This suggests that every euro invested has the potential to yield EUR58.85 annually in earnings. It's noteworthy to consider the company's intraday volatility over the past week and month which averaged at -1.50% and -0.25% respectively, but surprisingly saw a positive swing of 1.54% in its quarterly performance.

Key Indicator: Return on Equity

The company's Return on Equity (ROE) stands as a notable figure amidst the gloom. At 26.72%, the ROE signifies a strong business performance by showcasing the return generated on investors' equity. However, the recent negative stock performance advises potential investors to proceed with caution and to stringently assess both market and company-specific dynamics.

Looking Forward: Investment Strategy

Navigating the current financial landscape calls for broader perspectives. Prospective investors must not overlook the wider economic scenario and sector performance in analysing ADYEN's recent downfall. While financial metrics provide crucial insights, one must not forget the role of holistic decision making. ADYEN might have shown a quirk of profitability in its figures, but its performance and the prevailing market trends underline the necessity of strategic decision-making in trading activities.

More news about ADYEN (ADYEN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com